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Background: Cancer stem cells (CSCs) play a key role in the posthepatectomy recurrence of hepatocellular
carcinoma (HCC). CD133+ HCC cells exhibit liver CSC–like properties, and CSC differentiation–inducing therapy may
lead these cells to lose their self-renewal ability and may induce terminal differentiation, which may in turn allow
their malignant potential to be controlled. Because arsenic trioxide (As2O3) increases remission rates and prolongs
survival among patients with acute promyelocytic leukemia by inducing differentiation and apoptosis of leukemic
cells, we hypothesized that As2O3 might also inhibit HCC recurrence and prolong survival time after hepatectomy
by inducing differentiation of HCC CSCs.
Methods: We evaluated the As2O3 induced differentiation of human HCC CSCs and its mechanism in vitro, and we
investigated the effects of treatment with As2O3 on recurrence rates and median survival in a mouse xenograft
model.
Results: We found that As2O3 induced HCC CSC differentiation by down-regulating the expression of CD133 and
some stemness genes, thus inhibiting the cells’ self-renewal ability and tumorigenic capacity without inhibiting their
proliferation in vitro. In vivo experiments indicated that As2O3 decreased recurrence rates after radical resection and
prolonged survival in a mouse model. As2O3, which shows no apparent toxicity, may induce HCC CSC differentiation
by down-regulating the expression of GLI1.
Conclusions: We found that As2O3 induced HCC CSC differentiation, inhibited recurrence, and prolonged survival
after hepatectomy by targeting GLI1expression. Our results suggest that the clinical safety and utility of As2O3
should be further evaluated.
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Worldwide, hepatocellular carcinoma (HCC) is the fifth
most common cancer and the second leading cause of
cancer death in men, and the seventh most common
cancer and the sixth leading cause of cancer death in
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unless otherwise stated.choice for treatment of HCC, but the long-term progno-
sis remains unsatisfactory; the recurrence rate is high,
owing to the lack of an effective adjuvant therapy [2].
Fan et al. reported that the presence of circulating liver
cancer stem cells (CSCs) is closely related to HCC recur-
rence and metastasis after resection [3]. Recent studies
have suggested that antiangiogenic therapy can stimulate
tumor invasion and metastasis [4,5], and the mechanism
of this stimulation may also be related to CSCs [6].
CSCs have the ability to self-renew, to differentiate
into defined progeny, and, most importantly, to initiateLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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tumor progression, metastasis, and recurrence [7]. CSCs
also show resistance to chemotherapeutics and radiation
[8]. In HCC, CD133+ cells exhibit liver CSC–like proper-
ties, such as high clonogenicity, tumorigenicity, and
resistance to radiation [9-13]. In addition to CD133,
EpCAM [14], CD44 [13] and CD90 [15] have also been
used as markers for the identification of HCC CSCs.
Tang et al. reported that CD133 expression overlaps ex-
tensively with expression of EpCAM and CD44, which
suggests that stem cells marked by CD133/EpCAM and
possibly CD133/CD44 may have similar characteristics
and regulatory mechanisms [11]. Tang et al. also showed
that CD90 is expressed at very low levels in HCC cell
lines and clinical specimens. Other studies have shown
that the presence of CD133+ CSCs in HCC patients after
surgery is correlated with early recurrence and poor
prognosis [16,17]. Two studies have reported that hep-
atocyte nuclear factor 4 alpha and bone morphogenetic
protein 4 can promote the differentiation of CD133+
HCC stem cells, inhibition of self-renewal, and resist-
ance to chemotherapy [18,19]; and these results suggest
that inducing CSC differentiation is a promising ap-
proach to the treatment of HCC. However, the use of
differentiation-inducing drugs for HCC has not been
well explored.
A number of studies have shown that the Hedgehog
(HH) signaling pathway plays an important role in CSC
self-renewal and inhibition of tumor differentiation in
various cancers [20-23]. Targeting HH signaling has
been shown to inhibit self-renewal of melanoma CSCs
in vitro and to decrease their tumor initiation ability
in vivo [24]. In a clinical study, advanced basal cell car-
cinoma patients were found to benefit from inhibition of
HH signaling [25]. In HCC, GLI1 expression is signifi-
cantly correlated with tumor size and TNM stage; GLI1
expression is high in patients with early recurrence and
poorer overall survival [26]. Therefore, GLI1 may be a
useful target for the prevention of HCC recurrence after
surgery.
Arsenic trioxide (As2O3) induces differentiation and
apoptosis of acute promyelocytic leukemia (APL) cells
by binding to the PML-RARα oncoprotein [27], and
treatment with As2O3 has been shown to increase remis-
sion rates and prolong survival in patients [28]. Some
studies have shown that As2O3 inhibits the growth and
metastasis of HCC by inducing apoptosis [29,30], but a
clinical trial showed that treatment with As2O3 is not ef-
fective for patients with advanced HCC [31]. There have
been no reports of As2O3 preventing HCC recurrence or
inducing differentiation of HCC CSCs.
We hypothesized that As2O3 could induce differenti-
ation of CD133+ HCC cells through the HH-GLI path-
way, and also investigated whether As2O3 could inhibitHCC recurrence and prolong survival time after hepa-
tectomy in a mouse model.
Results
As2O3 reduced CD133 expression in HCC CSCs but did
dot inhibit proliferation at lower dosages
We used unmodified human hepatoma cell lines (Huh7-
wt and Hep3B-wt), which have a relatively high percentage
of CD133+ cells, to analyze the biologic effects of As2O3
on HCC CSCs. Various dosages of As2O3 (0–6 μM) were
used to explore its effects on CSC differentiation. We
found that in CD133+ cells, As2O3 significantly reduced
expression of CD133 mRNA and protein and that mRNA
expression decreased with increasing As2O3 concentration
(Figure 1A–C). Because 4 μM As2O3 significantly down-
regulated CD133 expression, we used this concentration
for subsequent tests. Flow cytometry results indicated
that treatment with As2O3 decreased the percentage of
CD133+ cells by more than 20% (Figure 1D).
To determine whether As2O3 inhibited proliferation of
CD133+ HCC cells, we performed a CCK8 cell proli-
feration assay, the results of which showed that As2O3
had little effect on CD133+ cell proliferation at 1–4 μM
(Figure 1E).
As2O3 down-regulated expression of stemness-associated
genes of HCC CSCs
To evaluate the alteration of stemness gene expression
during the process by which As2O3 induced differenti-
ation of HCC CSCs, we analyzed stemness gene expres-
sion by means of a Human Stem Cell RT2 Profiler PCR
Array after the CD133+ Huh7-wt cells had been treated
with 4 μM As2O3 for 48 hours. The data showed that re-
duced expression of CD133 after As2O3 treatment was
accompanied by down-regulation of 5 stemness genes
that are involved in the maintenance of pluripotency or
are richly expressed in human CSCs [13,32-35]: adeno-
sine deaminase, RNA-specific (ADAR); gap junction pro-
tein, beta 1, 32 kDa (GJB1); fibroblast growth factor 1
(acidic) (FGF1); deltex homolog 2 (Drosophila) (DTX2);
and wingless-type MMTV integration site family, mem-
ber 1 (WNT1) (Figure 2). These 5 stemness genes were
also down-regulated in CD133+ Hep3B-wt cells that had
been treated with 4 μM As2O3 for 48 hours, as indicated
by real-time polymerase chain reaction (Additional file 1:
Table S1).
As2O3 inhibited self-renewal and tumorigenic capacity of
HCC CSCs
The fundamental properties of CSCs are their ability to
self-renew and their ability to differentiate into defined
progeny. To evaluate the self-renewal potential of CD133+
cells after treatment with As2O3 in vitro, we used a
sphere-forming assay. We tested the sphere-formation
Figure 1 (See legend on next page.)
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Figure 1 As2O3 down-regulated CD133 expression in vitro and did not inhibit cell proliferation at lower dosages. (A–C) Treatment of
CD133+ HCC cells, with 2 μM As2O3 reduced CD133 mRNA expression after 24 hours and treatment with 1 μM As2O3 did so after 48 hours
(A, *P < 0.05) ; treatment with As2O3 also reduced CD133 protein expression (B,C; red, CD133; blue, 4′,6-diamidino-2-phenylindole; magnification,
×200). (D) After treatment with 4 μM As2O3 for 5 days, the percentage of CD133+ Huh7-wt cells decreased from 82.1% to 55.7% (upper panels)
and the percentage of CD133+ Hep3B-wt cells decreased from 76.1% to 43.8% (lower panels). (E) In a 48-hour assay, 6 μM As2O3 inhibited
proliferation of HCC CSCs, whereas As2O3 at 1–4 μM had little effect on proliferation over the course of 24 or 48 hours (*P < 0.05).
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for 5 days and found that tumor spheres generated from
CD133+ cells treated with As2O3 were fewer in number
and smaller in size than the spheres generated from un-
treated cells (Figure 3A).
To compare the tumorigenic potential of As2O3-
treated and untreated CD133+ HCC cells, we inoculated
NOD/SCID mice subcutaneously with 5 × 104 CD133+
Huh7-wt cells or 2 × 105 CD133+ Hep3B-wt cells, and
we found that tumor growth was inhibited by As2O3
treatment (Figure 3B).
As2O3 inhibited recurrence after curative resection and
improved survival in a mouse model
The incidences of intrahepatic tumor recurrence in the
control and As2O3-treated groups were 75% (9/12) and
33.33% (4/12) for the Huh7-GFP cell line and 91.67%
(11/12) and 41.67% (5/12) for the Hep3B-GFP cell line,
and the differences were statistically significant. No lung
metastasis was observed in either group. No animal ex-
perienced a weight loss of more than 10%, fever, or
anemia during the treatment regimen. We also found
there were no significant pathological changes in the
heart, spleen, or kidney of the mice in the As2O3 group.
Recurrence after resection is closely related to the
presence of circulating tumor cells (CTCs) in patients
with HCC [36]. Therefore, we compared the numbers of
CTCs in the As2O3 and control groups (Figure 4A) and
found that As2O3 treatment significantly decreased the
number of CTCs.
In both the Huh7-wt model and the Hep3B-wt model,
treatment with As2O3 for 4 weeks significantly pro-
longed survival (Figure 4B).
As2O3 down-regulated GLI1 expression via the HH signaling
pathway
To explore how As2O3 induced differentiation of CD133
+
HCC CSCs, we analyzed stem cell signaling–related gene
expression by using a Human Stem Cell Signaling RT2
Profiler PCR Array after the CD133+ Huh7-wt cells had
been treated with 4 μM As2O3 for 48 hours. We found
that As2O3 treatment down-regulated expression of GLI1
and PTCH1 (−10.13 fold, P = 0.0279); (Figure 5). Com-
bined with the results of the Human Stem Cell RT2
Profiler PCR Array, these results indicate that As2O3
down-regulated the expression of GLI1 and its downstreamtarget genes PTCH1 and WNT1, so we hypothesized
that As2O3 inhibited the expression of CD133 by down-
regulating GLI1. This hypothesis was confirmed by
Western blotting analysis in the CD133+ Huh7-wt and
CD133+ Hep3B-wt models (Figure 6A). Furthermore, we
found that knockdown of GLI1 expression or forced over-
expression of GLI1 significantly decreased or increased,
respectively, CD133 expression (Figure 6B). Huh7-LV-
shGLI1 and Hep3B-LV-shGLI1 cells were treated with
4 μM As2O3 for 48 hours, the expression of CD133 did
not decrease significantly (Figure 6C), and this results sup-
port the notion that As2O3 may decrease CD133 expres-
sion by targeting GLI1.
Discussion
The CSC theory is based on the fact that CSCs exhibit
properties similar to those of normal stem cells, such as
self-renewal, the ability to produce heterogeneous pro-
geny, and the ability to divide in an unlimited way, giving
rise to high tumorigenicity, chemotherapy and radiation
resistance, metastasis, and cancer recurrence after therapy
[8]. Therefore, CSCs have the potential to be effective tar-
gets for preventing relapse after resection, including in
HCC. Therapy involving induced differentiation of CSCs
could lead to the cells losing their self-renewal ability and
could induce terminal differentiation. To date, the best ex-
ample of the clinical use of differentiation-inducing ther-
apy is treatment of APL with all-trans retinoic acid, which
enhances the effects of chemotherapy and significantly
improves patient outcome [37]. Targeting induction of
CSC differentiation may be a powerful therapy for HCC.
CD133+ HCC cells are considered to be CSCs because of
their higher tumorigenicity [10] and lower expression of
mRNAs for mature hepatocyte markers [9]. As2O3, which
is an FDA-approved agent for the treatment of APL, can
induce APL cells differentiation. Our results revealed that
CD133 expression and the percentage of CD133+ cells
were dramatically decreased in both CD133+ Huh7-wt
and cd133+ Hep3B-wt cells treated with As2O3. But real-
time PCR analysis revealed that after the CSCs were
treated with As2O3 for 48 hours, a cluster of hepatocyte
marker genes—including phosphoenolpyruvate carboxyki-
nase, glucose-6-phosphatase, cytochrome P450, glutamine
synthetase, biliverdin reductase, aldolase B, apolipoprotein
c III, apolipoprotein A I, 4-hydroxyphenylpyruvate dioxy-
genase, and glycogen synthetase 2—were not re-expressed
Figure 2 As2O3 down-regulated expression of 5 stemness genes in HCC CSCs.
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Figure 3 As2O3 inhibited self-renewal and decreased the tumorigenic capacity of CD133
+ CSCs. (A) Pretreatment of CD133+ Huh7-wt and
CD133+ Hep3B-wt cells with 4 μM As2O3 for 5 days inhibited CSC sphere formation. (B) As2O3 also decreased the tumorigenicity of CD133
+ cells.
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treatment decreased the expression of some stemness
genes, which are important for the maintenance of CSC
self-renewal ability and tumorigenicity [13,38]. We also
found that high-dose As2O3 reduced CSC proliferation,
whereas low-dose As2O3 had no such effect. CSCs are
considered to be more resistant to chemotherapeutic
agents than non-CSCs, and consistent with this, low-dose
As2O3 has been found to inhibit Huh7-wt cell prolifera-
tion [39]. In short, low-dose As2O3 may induce HCC
CSCs differentiation into non-CSCs,which is very import-
ant for the clinical application of As2O3 because of its
toxicity.
It should be possible to treat cancer by differentiation-
inducing therapy targeted at CSCs. If CSCs could be in-
duced to differentiate, then their malignant potential
could be controlled [34]. We have shown that As2O3 in-
duced HCC CSC differentiation in vitro, and thus we
postulate that As2O3 may be useful for inhibiting recur-
rence of HCC after resection and may prolong survival
in vivo. The HCC recurrence rate was decreased by sys-
temic administration of As2O3, and survival time was
significantly prolonged. However, in a phase II clinical
trial, patients with advanced HCC did not benefit from
As2O3 treatment [31], and we believe that the effective
treatment of advanced HCC must involve a combination
of differentiation-inducing therapy and conventionalchemotherapies to eradicate the tumor mass, and this
belief is partly supported by the results of Wang et al.
[13]. Due to the toxic effects of As2O3 limits its clinical
application, we found that low-dosage of As2O3 can in-
duce differentiation of HCC CSCs and inhibit recur-
rence, so the application of As2O3 to prevent recurrence
of HCC patients after surgery may be an effective way.
We also found CTCs were decreased by As2O3 treat-
ment. Because the presence of CTCs is associated with
metastasis to distant organs and is strongly associated
with poor overall survival [40], we suggest that As2O3
could decrease metastasis and prolong survival. This
suggestion could be tested with other models.
The HH-GLI pathway is an important mechanism for
determining embryonic pattern and regulating cell fate
[11]. This pathway has been implicated in several types
of tumors [41] and plays an important role in the differ-
entiation of CSCs [20-23]. Differentiation of CSCs by in-
hibition of the HH-GLI pathway may be a promising
therapeutic strategy for human tumors. Currently, all the
therapeutics in clinical development that function by
inhibiting the HH-GLI pathway are targeted at SMO
[41]. However, in some types of tumors, specifically
those in which increased GLI expression or activation is
induced in a SMO-independent manner, SMO inhibitors
are ineffective, and inhibitors that modulate GLI may be
useful [42-44]. In HCC, expression of GLI1 mRNA has
Figure 4 As2O3 decreased the proportion of CTCs relative to peripheral blood mononuclear cells (PBMCs) and prolonged survival.
(A) Flow cytometry analysis indicated that As2O3 significantly decreased the proportion of CTCs relative to PBMCs, In the Huh7-GFP cell line, the
proportions of CTCs relative to PBMCs were 1.292% ± 0.164% in the As2O3 group and 1.758%± 0.118% in the control group (P = 0.0305), and in the
Hep3B-GFP cell line, the corresponding proportions were 0.619% ± 0.050% and 1.235%± 0.072% (P < 0.0001). (B) In the Huh7-wt cell line, median
survival increased from 72.5 to 86.5 days (P = 0.0344), and in the Hep3B-wt cell line, median survival increased from 89.5 to 104 days (P = 0.015).
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of patients with HCC after resection [26], which is con-
sistent with our results, As2O3 may induce CSC differen-
tiation by down-regulating the expression of GLI1, thus
inhibiting recurrence and prolonging survival.
Conclusion
In conclusion, As2O3 may induce HCC CSC differenti-
ation, inhibit cancer recurrence after radical resection,
and prolong survival as a result of down-regulation of
GLI1 expression. In in vivo tests, As2O3 shows no appar-
ent toxicity, but its clinical safety and utility must be
evaluated.
Methods
Cell culture and reagents
Unmodified Huh7 and Hep3B cells (Huh7-wt and Hep3B-
wt) were obtained from American Type Culture Collec-
tion. Cells from both cell lines were transfected with GFP(Huh7-GFP and Hep3B-GFP, respectively) as described
previously [45]. Huh7-LV-shGLI1 and Hep3B-LV-shGLI1
cells were obtained by infecting CD133+ Huh7-wt and
CD133+ Hep3B-wt with a lentiviral vector encoding short
hairpin RNA for GLI1 (sc-37911-V, Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) to silence its expression.
As controls, Huh7-LV-shNon and Hep3B-LV-shNon
cells were obtained by infection of CD133+ Huh7-wt and
CD133+ Hep3B-wt with a different lentiviral vector (sc-
108080, Santa Cruz Biotechnology). Huh7-LV-oeGLI1 and
Hep3B-LV-oeGLI cells were obtained by infecting CD133+
Huh7-wt and CD133+ Hep3B-wt with lentiviral vectors
that overexpress GLI1 (Genechem, Shanghai, P.R. China).
Huh7-LV-oeNon and Hep3B-LV-oeNon cells were also
used as controls (Genechem). All cell lines were cultured
in Dulbecco’s modified Eagle’s medium supplemented
with 10% fetal bovine serum.
As2O3 (SL Pharm, Beijing, P.R. China) was dissolved at
a concentration of 0.05 mg/ml in phosphate buffered
Figure 5 The results of Human Stem Cell Signaling RT2 Profiler PCR Array analysis indicated that As2O3 down-regulated the expression
of GLI1 and PTCH1 in CD133+ Huh7-wt cells.
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Figure 6 As2O3 down-regulated GLI1 expression via the Hedgehog signaling pathway. (A), As2O3 decreased GLI1 protein expression in
CD133+ Huh7-wt and CD133+ Hep3B-wt cells, as indicated by Western blotting analysis. (B), Short hairpin RNA knockdown of GLI1 expression
decreased CD133 expression in CD133+ Huh7-wt and CD133+ Hep3B-wt cells; similarly, up-regulation of GLI1 expression increased CD133
expression (wt = CD133+ Huh7-wt and CD133+ Hep3B-wt; control = Huh7-LV-shNon, Hep3B-LV-shNon, and Huh7-LV-oeNon, Hep3B-LV-oeNon;
sh = Huh7-LV-shGLI1 and Hep3B-LV-shGLI1; oe = Huh7-LV-oeGLI1 and Hep3B-LV-oeGLI1). (C), Huh7-LV-shGLI1 and Hep3B-LV-shGLI1 cells were
treated with 4 μM As2O3 for 48 hours, the expression of CD133 did not decrease significantly.
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As2O3 was dissolved in normal saline.Cell isolation by fluorescence-activated cell sorting
Huh7-wt and Hep3B-wt cells were labeled directly with
phycoerythrin-conjugated anti-human CD133/1 anti-
body (Miltenyi Biotec, Gladbach, Germany) according
to the manufacturer’s instruction and were sorted by
fluorescence-activated cell sorting to obtain CD133+cell subpopulations; a sorted cell purity exceeding 90%
was deemed acceptable for in vitro experiments.Cell proliferation assay
Cell proliferation was counted by a CCK8 assay (Dojindo,
Tokyo, Japan). Three thousand CD133+ cells were seeded
in 96-well culture plates. After adhesion for 24 hours, the
cells were treated with As2O3 at a final concentration ran-
ging from 1 to 6 μM, and the treated cells were cultured
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As2O3 were used as controls. The cell proliferation assay
was carried out as previously described [5]. The optical
density values were read by an enzyme-linked immuno-
sorbent assay reader at 450 nM.Real-time polymerase chain reaction analysis
Real-time PCR analysis was carried out as described as
elsewhere [5]. The following primers were used for
amplification of human genes: CD133 [18], forward 5′-
ACATGAAAAGACCTGGGGG-3′, reverse 5′- GATC
TGGTGT CCCAGCATG-3′; β-actin, forward 5′-GCT
CTGCAGACTTCAGACCA-3′, reverse 5′-GGCCGGA
CTCATCGTACTCCTGC-3′.Western blotting assay
The procedure used for Western blotting assay is
described elsewhere [5]. Primary antibodies included
anti-CD133/1 (Miltenyi Biotec), anti-GLI1 (Santa Cruz
Biotechnology), and anti-β-actin (Kangcheng Technology,
Shanghai, P.R. China).Immunofluorescence
To assess the distribution and changes of CD133 in
HCC CSCs after treatment with As2O3, we stained
CD133+ Huh7-wt and CD133+ Hep3B-wt cells for
visualization by means of an immunofluorescence assay.
Briefly, the cells were seeded on slides, allowed to adhere
for 24 hours, treated with As2O3 at a final concentration
ranging from 1 to 6 μM, and then cultured for another
24 or 48 hours. Cells that were not exposed to As2O3
were used as controls. The slides were washed with PBS
and fixed with 4% paraformaldehyde. The cells were in-
cubated with primary antibody to CD133/1 (Miltenyi
Biotec) overnight at 4°C after being blocked with 5% bo-
vine serum albumin, and then goat anti-mouse tetra-
methyl rhodamine isothiocyanate-conjugated secondary
antibody was added before staining with 4′,6-diamidino-
2-phenylindole. Fluorescence images were visualized with
an inverted fluorescence microscope (Olympus, Melville,
NY, USA). For a negative control, primary antibodies were
replaced with PBS.Flow cytometry analysis
The percentages of CD133+ cells were determined by
flow cytometry to evaluate the expression of CD133. Iso-
lated CD133+ HCC cells were incubated with or without
As2O3 for 5 days. The cells were trypsinized, washed,
and resuspended in PBS. Then the cells were incubated
with phycoerythrin-conjugated anti-CD133/1 antibody
(Miltenyi Biotec) on ice for 30 min and analyzed by
means of flow cytometry (BD Biosciences, USA).Culture of HCC CSC spheres
The self-renewal capability of HCC cells was evaluated by
testing their sphere-formation ability. Specifically isolated
CD133+ HCC cells treated with 4 μM As2O3 treatment
for 5 days and untreated cells were cultured in a methyl
cellulose–based medium in low-adherent 96-well culture
plates (Corning, Corning, NY, USA) under serum-free
conditions and supplemented with 20 μg/ml insulin,
20 μg/ml epidermal growth factor, and 10 μg/ml basic
fibroblast growth factor (RD Systems, Minneapolis, MN,
USA) according to a previously published procedure [46].
Single-cell suspensions of 100 CD133+ HCC cells were
seeded, and epidermal growth factor, basic fibroblast
growth factor, and insulin were added every second day
for 2 weeks.
Tumorigenic capacity of HCC CSCs
The tumorigenic capacity of 4 μM As2O3-treated and
untreated CD133+ HCC cells for 5 days were analyzed
in an NOD/SCID mouse xenograft model. Male NOD/
SCID mice (4–6 weeks old) were injected subcutane-
ously in the lateral flanks with 5 × 104 CD133+ Huh7-wt
cells and 2 × 105 CD133+ Hep3B-wt cells. Tumorigenic
capacity was evaluated after the cells had been allowed
to undergo implantation for 7 weeks.
Animal model
Male BALB/c nu/nu nude mice (Shanghai Institute of
Materia Medica, Chinese Academy of Science, Shanghai,
P.R. China) were housed in laminar-flow cabinets under
specific pathogen-free conditions and used when they
weighed approximately 20 g and were 4–6 weeks old. The
experimental protocol was approved by the Shanghai
Medical Experimental Animal Care Committee. The ani-
mal model was established as previously described [47].
Briefly, Huh7-wt, Hep3B-wt, Huh7-GFP, and Hep3B-GFP
cells (1 × 107) were subcutaneously inoculated into the
right flanks of the nude mice. After 3–4 weeks, a piece of
non-necrotic tumor tissue about 2 mm in size was ortho-
topically implanted into the liver. On the fourteenth day
after implantation, the tumor was excised, with the length
between incisional margin and tumor edge being ≥ 2 mm.
As2O3 treatment and grouping
The in vivo experiment involved 2 groups: a recurrence
rate group, which used the Huh7-GFP and Hep3B-GFP
cell lines, and a survival observation group, which used
the Huh7-wt and Hep3B-wt cell lines. In the recurrence
rate group, treatment was started on the fifth day after
resection. The mice were randomly assigned to 2 groups
(n = 12 for each group): one group received a daily intra-
peritoneal dose of 1.5 mg/kg As2O3, and the other group
received an equal volume of normal saline (control
group). The treatment was continued for 2 weeks, and
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orbital blood was obtained. The mice were then sacri-
ficed by cervical dislocation to determine the recurrence
rate.
In the survival group, treatment was started on the
fifth day after resection. The mice were randomly
assigned to 2 groups (n = 8 for each group): one group
received a daily intraperitoneal dose of 1.5 mg/kg As2O3,
and the other group received an equal volume of normal
saline (control group). The treatment was administered
for 2 weeks, then stopped for 1 week to allow the mice
to recover, and then administered for an additional
2 weeks; then the median survival was determined.
Detection of CTCs
CTCs in the peripheral blood of mice in the recurrence
group were counted by flow cytometry, with GFP as a
marker. The protocol was carried out as previously re-
ported [15]. The GFP-positive cells were gated with
processed blood from a mouse that had not been sub-
jected to the xenograft procedure.
PCR microarray analysis of stemness gene expression and
pathway exploration
Total RNA was extracted from isolated As2O3-treated and
untreated CD133+ HCC cells and was analyzed by means
of a Human Stem Cell RT2 Profiler PCR Array (http://
www.sabiosciences.com/rt_pcr_product/HTML/PAHS-
405Z.html) and a Human Stem Cell Signaling RT2 Pro-
filer PCR Array (http://www.sabiosciences.com/rt_pcr_
product/HTML/PAHS-047Z.html), according to the
manufacturer’s instructions.
Statistical analysis
Values for continuous variables are expressed as means ±
SDs and were compared by means of the unpaired 2-tailed
Student t test, unless otherwise specified, Multiple com-
parisons of Kaplan-Meier curves were made using the log-
rank test. All statistical tests were performed using SPSS
for Windows (ver. 120.0, SPSS, Inc). P < 0.05 (2-tailed) was
considered to indicate statistical significance.
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Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
ZKZ designed the study, established the animal model, carried out the
Western blotting assays, performed the statistical analysis, and drafted the
manuscript. ZQB and ZQB participated in the design of the study, data
analysis, and drafting the manuscript. SHC participated in the design of thestudy and helped to draft the manuscript. AJY, CZT, ZXD, LL, ZYY, BY, and
KLQ helped to acquire experimental data. TZY conceived the study,
participated in its design and coordination, and helped to draft the
manuscript. All authors read and approved the final manuscript.Acknowledgements
This project was supported by the National Natural Science Foundation of
China (grant nos. 81101564, 81020108025), the Shanghai Natural Science
Fund for Youth Scholars (12ZR1442300), and the National Key Project for
Infectious Diseases (2012ZX10002012-004). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Author details
1Liver Cancer Institute and Zhongshan Hospital, Fudan University, Key
Laboratory for Carcinogenesis and Cancer Invasion, The Chinese Ministry of
Education, 136 Yi Xue Yuan Road, Shanghai 200032, P R China. 2Department
of General Surgery, Qilu Hospital, Shandong University, Jinan 250012, P R
China.
Received: 29 December 2013 Accepted: 20 March 2014
Published: 30 March 2014References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer
statistics. CA Cancer J Clin 2011, 61:69–90.
2. Fan ST, Mau Lo C, Poon RT, Yeung C, Leung Liu C, Yuen WK, Ming Lam C,
Ng KK, Ching Chan S: Continuous improvement of survival outcomes of
resection of hepatocellular carcinoma: a 20-year experience. Ann Surg
2011, 253:745–758.
3. Fan ST, Yang ZF, Ho DW, Ng MN, Yu WC, Wong J: Prediction of
posthepatectomy recurrence of hepatocellular carcinoma by circulating
cancer stem cells: a prospective study. Ann Surg 2011, 254:569–576.
4. Loges S, Mazzone M, Hohensinner P, Carmeliet P: Silencing or fueling
metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer cell
2009, 15:167–170.
5. Zhang W, Sun HC, Wang WQ, Zhang QB, Zhuang PY, Xiong YQ, Zhu XD, Xu
HX, Kong LQ, Wu WZ, Wang L, Song TQ, Li Q, Tang ZY: Sorafenib down-
regulates expression of HTATIP2 to promote invasiveness and metastasis
of orthotopic hepatocellular carcinoma tumors in mice. Gastroenterology
2012, 143:1641–1649. e1645.
6. Tanaka S, Arii S: Molecular targeted therapy for hepatocellular carcinoma
in the current and potential next strategies. J Gastroenterol 2011,
46:289–296.
7. Jordan CT, Guzman ML, Noble M: Cancer stem cells. N Engl J Med 2006,
355:1253–1261.
8. Tong CM, Ma S, Guan XY: Biology of hepatic cancer stem cells.
J Gastroenterol Hepatol 2011, 26:1229–1237.
9. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H:
Characterization of CD133+ hepatocellular carcinoma cells as cancer
stem/progenitor cells. Biochem Biophys Res Commun 2006, 351:820–824.
10. Yin S, Li J, Hu C, Chen X, Yao M, Yan M, Jiang G, Ge C, Xie H, Wan D, Yang
S, Zheng S, Gu J: CD133 positive hepatocellular carcinoma cells possess
high capacity for tumorigenicity. Int J Cancer J int du cancer 2007,
120:1444–1450.
11. Tang KH, Ma S, Lee TK, Chan YP, Kwan PS, Tong CM, Ng IO, Man K, To KF,
Lai PB, Lo CM, Guan XY, Chan KW: CD133(+) liver tumor-initiating cells
promote tumor angiogenesis, growth, and self-renewal through
neurotensin/interleukin-8/CXCL1 signaling. Hepatology 2012, 55:807–820.
12. Piao LS, Hur W, Kim TK, Hong SW, Kim SW, Choi JE, Sung PS, Song MJ, Lee
BC, Hwang D, Yoon SK: CD133+ liver cancer stem cells modulate
radioresistance in human hepatocellular carcinoma. Cancer Lett 2012,
315:129–137.
13. Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO, Zheng BJ, Guan XY:
Identification and characterization of tumorigenic liver cancer stem/
progenitor cells. Gastroenterology 2007, 132:2542–2556.
14. Warrell RP Jr, Frankel SR, Miller WH Jr, Scheinberg DA, Itri LM, Hittelman WN,
Vyas R, Andreeff M, Tafuri A, Jakubowski A, Gabrilove J, Gordon MS,
Dmitrovsky E: Differentiation therapy of acute promyelocytic leukemia
with tretinoin (all-trans-retinoic acid). N Engl J Med 1991, 324:1385–1393.
Zhang et al. Journal of Hematology & Oncology 2014, 7:28 Page 12 of 12
http://www.jhoonline.org/content/7/1/2815. Jiang J, Hui CC: Hedgehog signaling in development and cancer. Dev Cell
2008, 15:801–812.
16. Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K: Expression and
clinical significance of the stem cell marker CD133 in hepatocellular
carcinoma. Int J Clin Pract 2008, 62:1212–1218.
17. Giampieri R, Scartozzi M, Loretelli C, Piva F, Mandolesi A, Lezoche G, Del
Prete M, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Guerrieri M, Bearzi I,
Cascinu S: Cancer stem cell gene profile as predictor of relapse in high
risk stage II and stage III, radically resected colon cancer patients.
PloS one 2013, 8:e72843.
18. Yin C, Lin Y, Zhang X, Chen YX, Zeng X, Yue HY, Hou JL, Deng X, Zhang JP,
Han ZG, Xie WF: Differentiation therapy of hepatocellular carcinoma in
mice with recombinant adenovirus carrying hepatocyte nuclear
factor-4alpha gene. Hepatology 2008, 48:1528–1539.
19. Zhang L, Sun H, Zhao F, Lu P, Ge C, Li H, Hou H, Yan M, Chen T, Jiang G,
Xie H, Cui Y, Huang X, Fan J, Yao M, Li J: BMP4 administration induces
differentiation of CD133+ hepatic cancer stem cells, blocking their
contributions to hepatocellular carcinoma. Cancer Res 2012, 72:4276–4285.
20. Varnat F, Duquet A, Malerba M, Zbinden M, Mas C, Gervaz P, Ruiz I, Altaba
A: Human colon cancer epithelial cells harbour active HEDGEHOG-GLI
signalling that is essential for tumour growth, recurrence, metastasis and
stem cell survival and expansion. EMBO Mol Med 2009, 1:338–351.
21. Song Z, Yue W, Wei B, Wang N, Li T, Guan L, Shi S, Zeng Q, Pei X, Chen L:
Sonic hedgehog pathway is essential for maintenance of cancer
stem-like cells in human gastric cancer. PloS one 2011, 6:e17687.
22. Zhang S, Wang Y, Mao JH, Hsieh D, Kim IJ, Hu LM, Xu Z, Long H, Jablons
DM, You L: Inhibition of CK2alpha down-regulates Hedgehog/Gli
signaling leading to a reduction of a stem-like side population in human
lung cancer cells. PloS one 2012, 7:e38996.
23. Fu J, Rodova M, Roy SK, Sharma J, Singh KP, Srivastava RK, Shankar S: GANT-
61 inhibits pancreatic cancer stem cell growth in vitro and in NOD/SCID/
IL2R gamma null mice xenograft. Cancer Lett 2013, 330:22–32.
24. Santini R, Vinci MC, Pandolfi S, Penachioni JY, Montagnani V, Olivito B, Gattai
R, Pimpinelli N, Gerlini G, Borgognoni L, Stecca B: Hedgehog-GLI signaling
drives self-renewal and tumorigenicity of human melanoma-initiating
cells. Stem Cells 1808–1818, 2012:30.
25. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R, Weiss GJ,
Borad MJ, Hann CL, Brahmer JR, Mackey HM, Lum BL, Darbonne WC,
Marsters JC Jr, de Sauvage FJ, Low JA: Inhibition of the hedgehog
pathway in advanced basal-cell carcinoma. N Engl J Med 2009,
361:1164–1172.
26. Jeng KS, Sheen IS, Jeng WJ, Lin CC, Lin CK, Su JC, Yu MC, Fang HY: High
expression of patched homolog-1 messenger RNA and glioma-
associated oncogene-1 messenger RNA of sonic hedgehog signaling
pathway indicates a risk of postresection recurrence of hepatocellular
carcinoma. Ann Surg Oncol 2012.
27. Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX,
Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou
GB, Tong JH, Zhang Y, Wu JH, Hu HY, De The H, Chen SJ, Chen Z: Arsenic
trioxide controls the fate of the PML-RARalpha oncoprotein by directly
binding PML. Science 2010, 328:240–243.
28. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M,
Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS,
Sayegh MH, Frank MH: Identification of cells initiating human melanomas.
Nature 2008, 451:345–349.
29. Oketani M, Kohara K, Tuvdendorj D, Ishitsuka K, Komorizono Y, Ishibashi K,
Arima T: Inhibition by arsenic trioxide of human hepatoma cell growth.
Cancer lett 2002, 183:147–153.
30. Kito M, Matsumoto K, Wada N, Sera K, Futatsugawa S, Naoe T, Nozawa Y,
Akao Y: Antitumor effect of arsenic trioxide in murine xenograft model.
Cancer Sci 2003, 94:1010–1014.
31. Lin CC, Hsu C, Hsu CH, Hsu WL, Cheng AL, Yang CH: Arsenic trioxide in
patients with hepatocellular carcinoma: a phase II trial. Invest New Drugs
2007, 25:77–84.
32. Nieto-Miguel T, Calonge M, de la Mata A, Lopez-Paniagua M, Galindo S, de
la Paz MF, Corrales RM: A comparison of stem cell-related gene
expression in the progenitor-rich limbal epithelium and the
differentiating central corneal epithelium. Mol Vis 2011, 17:2102–2117.
33. Barbash O, Zamfirova P, Lin DI, Chen X, Yang K, Nakagawa H, Lu F, Rustgi
AK, Diehl JA: Mutations in Fbx4 inhibit dimerization of the SCF(Fbx4)ligase and contribute to cyclin D1 overexpression in human cancer.
Cancer cell 2008, 14:68–78.
34. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, Zhu Y: Induction of
abnormal proliferation by nonmyelinating schwann cells triggers
neurofibroma formation. Cancer cell 2008, 13:117–128.
35. Luo Y, Dallaglio K, Chen Y, Robinson WA, Robinson SE, McCarter MD, Wang
J, Gonzalez R, Thompson DC, Norris DA, Roop DR, Vasiliou V, Fujita M:
ALDH1A isozymes are markers of human melanoma stem cells and
potential therapeutic targets. Stem Cells 2012, 30:2100–2113.
36. Liu JW, Hsu YC, Kao CY, Su HL, Chiu IM: Leukemia inhibitory factor-
induced Stat3 signaling suppresses fibroblast growth factor 1-induced
Erk1/2 activation to inhibit the downstream differentiation in mouse
embryonic stem cells. Stem Cells Dev 2013, 22:1190–1197.
37. Krause DS, Crispino JD: Molecular pathways: induction of polyploidy as a
novel differentiation therapy for leukemia. Clin Cancer Res 2013,
19:6084–6088.
38. Anastas JN, Moon RT: WNT signalling pathways as therapeutic targets in
cancer. Nat Rev Cancer 2012, 13:11–26.
39. Kito M, Akao Y, Ohishi N, Yagi K, Nozawa Y: Arsenic trioxide-induced
apoptosis and its enhancement by buthionine sulfoximine in
hepatocellular carcinoma cell lines. Biochem Biophys Res Commun 2002,
291:861–867.
40. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian
LM, Richmond A, Lin PC, Moses HL: Abrogation of TGF beta signaling in
mammary carcinomas recruits Gr-1 + CD11b +myeloid cells that
promote metastasis. Cancer cell 2008, 13:23–35.
41. Ng JM, Curran T: The Hedgehog’s tale: developing strategies for targeting
cancer. Nat Rev Cancer 2011, 11:493–501.
42. Zwerner JP, Joo J, Warner KL, Christensen L, Hu-Lieskovan S, Triche TJ, May
WA: The EWS/FLI1 oncogenic transcription factor deregulates GLI1.
Oncogene 2008, 27:3282–3291.
43. Beauchamp E, Bulut G, Abaan O, Chen K, Merchant A, Matsui W, Endo Y,
Rubin JS, Toretsky J, Uren A: GLI1 is a direct transcriptional target of
EWS-FLI1 oncoprotein. J Biol Chem 2009, 284:9074–9082.
44. Nolan-Stevaux O, Lau J, Truitt ML, Chu GC, Hebrok M, Fernandez-Zapico ME,
Hanahan D: GLI1 is regulated through Smoothened-independent
mechanisms in neoplastic pancreatic ducts and mediates PDAC cell
survival and transformation. Genes Dev 2009, 23:24–36.
45. Jiang X, Tan J, Li J, Kivimae S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton
LW, Liu ET, Cheyette BN, Yu Q: DACT3 is an epigenetic regulator of Wnt/
beta-catenin signaling in colorectal cancer and is a therapeutic target of
histone modifications. Cancer cell 2008, 13:529–541.
46. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE: Drug-selected
human lung cancer stem cells: cytokine network, tumorigenic and
metastatic properties. PloS one 2008, 3:e3077.
47. Wang L, Tang ZY, Qin LX, Wu XF, Sun HC, Xue Q, Ye SL: High-dose and
long-term therapy with interferon-alfa inhibits tumor growth and
recurrence in nude mice bearing human hepatocellular carcinoma
xenografts with high metastatic potential. Hepatology 2000, 32:43–48.
doi:10.1186/1756-8722-7-28
Cite this article as: Zhang et al.: Arsenic trioxide induces differentiation
of CD133+ hepatocellular carcinoma cells and prolongs
posthepatectomy survival by targeting GLI1 expression in a mouse
model. Journal of Hematology & Oncology 2014 7:28.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
